PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
23.98%
G&A growth 50-75% of CRVO's 37.03%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses growth less than half of CRVO's 100.00%. David Dodd would verify if advantage is sustainable.
15.26%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
15.26%
Similar total costs growth to CRVO's 15.98%. Walter Schloss would investigate norms.
-36.68%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
7.46%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
-50.67%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-50.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-50.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-43.14%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.01%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
5.01%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.